Strides Pharma hits 52-week low, slumps 9% on weak Q2 results

The management said a muted sales performance accompanied with a drop in gross margins and relatively higher operating costs has led to a negative operating leverage in H1

from Latest News https://ift.tt/3wBi74q
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share